ntrk1

Migration, Crosslink

📖

ntrk1

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-ntrk1

📖 Wiki Page

general2045 wordssynced 2026-04-02

NTRK1 Gene - Neurotrophic Receptor Tyrosine Kinase 1

Introduction

The NTRK1 gene (Neurotrophic Receptor Tyrosine Kinase 1) encodes the TrkA (Tropomyosin receptor kinase A) receptor, the high-affinity receptor for nerve growth factor (NGF). TrkA is a member of the tropomyosin receptor kinase (Trk) family, which plays critical roles in neuronal survival, differentiation, and function throughout the nervous system. Originally discovered as the receptor for NGF, TrkA has since emerged as a key therapeutic target for multiple neurological disorders, particularly Alzheimer's disease and peripheral neuropathies.

Mutations in NTRK1 cause congenital insensitivity to pain with anhidrosis (CIPA), a rare autosomal recessive disorder characterized by complete loss of pain sensation, anhidrosis (inability to sweat), and often intellectual disability. This demonstrates the essential role of TrkA signaling in pain perception and thermoregulation.

Gene Overview

| Property | Value |
|----------|-------|
| Gene Symbol | NTRK1 |
| Full Name | Neurotrophic Receptor Tyrosine Kinase 1 |
| Alternative Names | TRKA, TrkA |
| Chromosomal Location | 1q21-q22 |
| NCBI Gene ID | 4914 |
| OMIM | 191315 |
| Ensembl ID | ENSG00000164329 |
| UniProt | P35579 |
| Protein Family | Tropomyosin receptor kinase (Trk) family |

...

NTRK1 Gene - Neurotrophic Receptor Tyrosine Kinase 1

Introduction

The NTRK1 gene (Neurotrophic Receptor Tyrosine Kinase 1) encodes the TrkA (Tropomyosin receptor kinase A) receptor, the high-affinity receptor for nerve growth factor (NGF). TrkA is a member of the tropomyosin receptor kinase (Trk) family, which plays critical roles in neuronal survival, differentiation, and function throughout the nervous system. Originally discovered as the receptor for NGF, TrkA has since emerged as a key therapeutic target for multiple neurological disorders, particularly Alzheimer's disease and peripheral neuropathies.

Mutations in NTRK1 cause congenital insensitivity to pain with anhidrosis (CIPA), a rare autosomal recessive disorder characterized by complete loss of pain sensation, anhidrosis (inability to sweat), and often intellectual disability. This demonstrates the essential role of TrkA signaling in pain perception and thermoregulation.

Gene Overview

| Property | Value |
|----------|-------|
| Gene Symbol | NTRK1 |
| Full Name | Neurotrophic Receptor Tyrosine Kinase 1 |
| Alternative Names | TRKA, TrkA |
| Chromosomal Location | 1q21-q22 |
| NCBI Gene ID | 4914 |
| OMIM | 191315 |
| Ensembl ID | ENSG00000164329 |
| UniProt | P35579 |
| Protein Family | Tropomyosin receptor kinase (Trk) family |

The TrkA receptor is a transmembrane protein composed of an extracellular ligand-binding domain, a transmembrane helix, and an intracellular tyrosine kinase domain. Upon NGF binding, TrkA dimerizes and activates intracellular signaling cascades that promote neuronal survival and function[@barbacid1999].

Protein Structure and Function

Receptor Architecture

The TrkA protein contains several distinct domains:

Extracellular Domain (amino acids 1-410):

Leucine-rich repeat (LRR) motifs for ligand binding
Cysteine-rich clusters
Immunoglobulin-like domains
Responsible for high-affinity NGF binding

Transmembrane Domain (amino acids 411-435):

Single alpha-helical segment
Anchors receptor in the plasma membrane

Intracellular Domain (amino acids 436-796):

Tyrosine kinase catalytic domain
Multiple tyrosine residues for phosphorylation
Sites for adaptor protein binding

Signal Transduction Pathways

TrkA activates multiple downstream signaling cascades upon NGF binding[@reichardt2006][@patapoutian2001]:

PI3K/Akt Pathway

The phosphoinositide 3-kinase (PI3K)/Akt pathway is critical for neuronal survival:

Activation: Autophosphorylation of TrkA creates docking sites for PI3K adaptor proteins (e.g., Shc, IRS-1)
PI3K activation: Generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3)
Akt activation: PIP3 recruits Akt to the membrane where it is phosphorylated and activated
Survival effects: Akt phosphorylates and inhibits pro-apoptotic proteins (Bad, caspase-9)
Metabolic regulation: Akt promotes glucose metabolism and protein synthesis

This pathway is particularly important for protecting neurons against [amyloid-beta](/proteins/amyloid-beta) toxicity in Alzheimer's disease.

MAPK/ERK Pathway

The mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway regulates:

Neuronal differentiation: Promotes neurite outgrowth and dendritic arborization
Synaptic plasticity: Modifies synaptic strength and structure
Gene expression: Activates transcription factors (e.g., CREB) that promote neuronal survival
Cell cycle: ERK1/2 activation can support neuronal survival under certain conditions

The MAPK pathway is essential for activity-dependent gene expression that underlies learning and memory.

PLC-γ Pathway

Phospholipase C-gamma (PLC-γ) signaling modulates:

Calcium signaling: PLC-γ hydrolyzes PIP2 to generate inositol trisphosphate (IP3) and diacylglycerol (DAG)
IP3 receptors: IP3 triggers calcium release from ER stores
Protein kinase C: DAG activates PKC isoforms
Synaptic transmission: Calcium dynamics modulate neurotransmitter release

This pathway integrates neurotrophin signaling with synaptic plasticity mechanisms.

Physiological Roles

TrkA signaling regulates multiple critical functions in the nervous system[@sofroniew2001][@lonze2002]:

Neuronal Survival: NGF-TrkA signaling prevents apoptosis during development and in adulthood

Differentiation: Promotes differentiation of neural progenitor cells into cholinergic and nociceptive neurons

Synaptic Plasticity: Modulates neurotransmitter release and receptor trafficking

Pain Perception: Essential for the development and maintenance of nociceptive pathways

Thermoregulation: Critical for thermal sensation and sweating

Expression Pattern

Tissue Distribution

NTRK1 exhibits selective expression in specific neuronal populations:

| Tissue/Cell Type | Expression | Functional Significance |
|-----------------|------------|------------------------|
| Nociceptive sensory neurons | High | Pain perception |
| Sympathetic neurons | High | Autonomic function |
| Basal forebrain cholinergic neurons | Moderate-High | Memory/learning |
| Melanocytes | High | Pigmentation |
| Mast cells | Moderate | Inflammatory response |

Brain Expression

Within the central nervous system, TrkA is prominently expressed in:

Basal forebrain cholinergic neurons (BFCNs): The major source of cortical cholinergic innervation
Hippocampal pyramidal neurons: Critical for memory formation
Certain cortical interneurons: Modulatory function
Sensory relay nuclei: Pain and temperature processing

The expression in basal forebrain cholinergic neurons is particularly relevant to Alzheimer's disease, as these neurons are preferentially lost in AD and are essential for attention and memory.

Disease Associations

Congenital Insensitivity to Pain with Anhidrosis (CIPA)

Mutations in NTRK1 cause CIPA (HSAN type IV), characterized by:

Complete loss of pain sensation: No response to painful stimuli
Anhidrosis: Inability to sweat, leading to temperature dysregulation
Intellectual disability: Often present, variable severity
Self-mutilation: Patients may inadvertently injure themselves

Over 200 pathogenic mutations have been identified in the NTRK1 gene, spanning the entire coding sequence. These mutations impair NGF binding, receptor dimerization, tyrosine kinase activity, or intracellular trafficking[@indo1996][@mardy1999].

Alzheimer's Disease

The NGF-TrkA pathway is considered a major therapeutic target for Alzheimer's disease for several reasons[@cuello1995][@tuszynski2005]:

Cholinergic Neuron Survival

Basal forebrain cholinergic neurons (BFCNs) are:

Essential for attention, learning, and memory
Preferentially lost in AD (early and severe degeneration)
Dependent on NGF for survival and function

TrkA activation by NGF promotes BFCN survival through the PI3K/Akt pathway, protecting these neurons from amyloid-beta toxicity and apoptosis.

Neuroprotective Effects

NGF-TrkA signaling provides multiple neuroprotective effects in AD models:

Anti-amyloid effects: Reduces amyloid-beta production and aggregation

Anti-tau effects: Inhibits tau phosphorylation and aggregation

Synaptic protection: Preserves synaptic structure and function

Anti-inflammatory: Modulates microglial activation

Metabolic support: Enhances neuronal energy metabolism

Clinical Trials

NGF gene therapy for AD has been explored in clinical trials:

Phase I trial (Tuszynski et al., 2005): Ex vivo NGF delivery via fibroblasts
Results: Showed promising evidence of cholinergic neuron preservation
Challenges: Delivery methods, side effects (weight loss, pain), and dosing
Current approaches: AAV-mediated gene delivery, small molecule TrkA agonists

Therapeutic Strategies

Several approaches target the NGF-TrkA pathway in AD:

NGF protein delivery: Direct NGF administration (challenging due to blood-brain barrier)
Gene therapy: AAV-based NGF or TrkA delivery
Small molecule agonists: Cell-penetrating NGF mimetics
TrkB/TrkC cross-activation: Broader neurotrophin receptor activation

Parkinson's Disease

TrkA activation may provide neuroprotective effects in Parkinson's disease:

Dopaminergic neuron survival: NGF supports dopaminergic neuron viability
Oxidative stress reduction: TrkA signaling upregulates antioxidant defenses
Neuroinflammation modulation: Reduces microglial activation
alpha-synuclein dynamics: May affect protein aggregation pathways

While not as advanced as AD research, NGF/TrkA strategies are being explored for PD.

Neuroblastoma

NTRK1 expression in neuroblastoma has complex clinical implications:

High expression correlates with favorable prognosis
Reactivation can occur in some tumors
Chromosomal rearrangements create oncogenic fusion proteins (e.g., TPM3-NTRK1)
Therapeutic targeting: Larotrectinib and other TRK inhibitors are effective in NTRK fusion-positive tumors[@brodeur2014]

Pathophysiology in Neurodegeneration

Mechanisms of Neuroprotection

The NGF-TrkA pathway protects neurons through multiple interconnected mechanisms:

1. Anti-apoptotic Signaling

The PI3K/Akt pathway:

Phosphorylates and inhibits Bad (pro-apoptotic BCL-2 family member)
Inactivates caspase-9
Promotes survival gene expression via CREB
Maintains mitochondrial integrity

This is particularly important for BFCNs, which are highly vulnerable to amyloid toxicity.

2. Amyloid-beta Modulation

NGF-TrkA signaling affects amyloid pathology through:

Reduced amyloid precursor protein (APP) processing
Enhanced amyloid clearance
Protection of neurons from amyloid-induced toxicity
Modulation of amyloid-degrading enzymes

3. Tau Phosphorylation Regulation

TrkA activation influences tau pathology:

Inhibits GSK-3β (major tau kinase)
Reduces tau hyperphosphorylation
Protects against tau-induced neurodegeneration
Maintains microtubule stability

4. Synaptic Function

TrkA signaling supports synaptic health:

Preserves cholinergic synapse structure
Enhances acetylcholine release
Promotes dendritic spine formation
Supports activity-dependent plasticity

Why Cholinergic Neurons Are Vulnerable

BFCNs are particularly susceptible in AD for several reasons:

NGF dependence: Their survival and function are critically dependent on NGF

High metabolic demand: Substantial energy requirements for acetylcholine synthesis

Axonal projection: Long axons are vulnerable to damage

Trophic factor access: Axonal transport of NGF can be impaired

Cellular stress: High baseline activity increases vulnerability

TrkA dysfunction may accelerate cholinergic degeneration, contributing to the characteristic cognitive decline in AD.

Therapeutic Implications

Current Approaches

Several therapeutic strategies target the NGF-TrkA pathway:

Protein and Gene Therapy

NGF protein delivery: Tested in clinical trials; challenges include delivery and side effects
AAV-NGF: Viral vector-mediated NGF expression in the brain
AAV-TrkA: Enhanced TrkA signaling in target neurons
Cell-based delivery: Ex vivo gene therapy using engineered cells

Small Molecule Agonists

NGF mimetics: Peptide or small molecule ligands that activate TrkA
Allosteric activators: Compounds that enhance NGF binding or TrkA activation
Cell-penetrating variants: Modified NGF that crosses the blood-brain barrier

Advantages of TrkA Agonists

Compared to NGF itself:

Smaller molecular weight
Better pharmacokinetic properties
Reduced off-target effects (e.g., p75NTR)
More selective TrkA activation

Clinical Development

Challenges and considerations:

Blood-brain barrier: Delivery to the CNS remains difficult

Dosing: Finding the optimal therapeutic window

Side effects: Pain, weight loss observed in some trials

Biomarkers: Need for objective measures of target engagement

Combination therapy: Potential synergy with other AD approaches

Future Directions

Promising research areas include:

Selective TrkA agonists with improved CNS penetration
Nanoparticle delivery systems for targeted NGF/agonist delivery
Gene editing approaches to enhance TrkA signaling
Biomarker development to select patients and monitor response
Combination strategies with anti-amyloid or anti-tau therapies

[NGF (Nerve Growth Factor)](/entities/ngf) — Primary ligand for TrkA
[BDNF](/entities/bdnf) — Brain-derived neurotrophic factor, TrkB ligand
[ChAT (Choline Acetyltransferase)](/entities/choline-acetyltransferase) — Acetylcholine synthesis enzyme
[APP (Amyloid Precursor Protein)](/genes/app) — Amyloid-beta precursor
[Tau](/proteins/tau) — Microtubule-associated protein

References

[Barbacid M, et al. Trk receptors: from biology to disease. Current Opinion in Neurobiology. 1999.](https://pubmed.ncbi.nlm.nih.gov/10525260/)

[Indo Y, et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. American Journal of Human Genetics. 1996.](https://pubmed.ncbi.nlm.nih.gov/8757039/)

[Mardy S, et al. Congenital insensitivity to pain with anhidrosis: novel mutations in the TRKA (NTRK1) gene. American Journal of Medical Genetics. 1999.](https://pubmed.ncbi.nlm.nih.gov/10331578/)

[Brodeur GM, et al. Trk receptors in neuroblastoma: clinical implications and therapeutic opportunities. Clinical Cancer Research. 2014.](https://pubmed.ncbi.nlm.nih.gov/24218515/)

[Tuszynski MH, et al. Nerve growth factor gene therapy for Alzheimer disease. Archives of Neurology. 2005.](https://pubmed.ncbi.nlm.nih.gov/15718510/)

[Sofroniew MV, et al. Nerve growth factor signaling, neuroprotection, and neural repair. Annual Review of Neuroscience. 2001.](https://pubmed.ncbi.nlm.nih.gov/11544116/)

[Cuello AC, et al. NGF and the treatment of Alzheimer's disease. Progress in Brain Research. 1995.](https://pubmed.ncbi.nlm.nih.gov/8743903/)

[Lonze BE, et al. Nerve growth factor, signal transduction, and neural circuit function in the hippocampus. BioEssays. 2002.](https://pubmed.ncbi.nlm.nih.gov/12223610/)

[Reichardt LF, et al. Neurotrophin-regulated signalling pathways. Philosophical Transactions of the Royal Society B. 2006.](https://pubmed.ncbi.nlm.nih.gov/16633346/)

[Patapoutian A, et al. Signaling by neurotrophins and their receptors. Cell. 2001.](https://pubmed.ncbi.nlm.nih.gov/11413491/)

[Chen ZY, et al. Nerve growth factor and its receptors in the mammalian central nervous system. Progress in Neuropsychopharmacology. 2007.](https://pubmed.ncbi.nlm.nih.gov/17493566/)

[Heasley LE, et al. Signal transduction pathways in neuroprotection and neurodegeneration. Journal of Neurology. 1997.](https://pubmed.ncbi.nlm.nih.gov/9034051/)

[Xie Y, et al. Tropomyosin-related kinase (Trk) signaling in neuronal survival. Journal of Neurobiology. 1999.](https://pubmed.ncbi.nlm.nih.gov/10607432/)

[Longo FM, et al. Small molecule neurotrophin receptor agonists and antagonists as therapeutic agents. Advances in Neurobiology. 2014.](https://pubmed.ncbi.nlm.nih.gov/25236733/)

[Ibanez CF, et al. Therapeutic targeting of neurotrophin signaling: progress and challenges. Trends in Pharmacological Sciences. 2018.](https://pubmed.ncbi.nlm.nih.gov/30100298/)

[Niewiadomska G, et al. Nerve growth factor and cholinergic neurons in Alzheimer's disease: from pathophysiology to therapeutic approaches. Journal of Alzheimer's Disease. 2021.](https://pubmed.ncbi.nlm.nih.gov/34092654/)

[Counts SE, et al. Neurotrophic factors in Alzheimer's disease: the role of NGF, BDNF, and CNTF in synaptic plasticity and cognitive function. Neurobiology of Learning and Memory. 2021.](https://pubmed.ncbi.nlm.nih.gov/34537562/)

[Mowla SJ, et al. Differential sorting of nerve growth factor and brain-derived neurotrophic factor in neurons. Neuroscience Letters. 1999.](https://pubmed.ncbi.nlm.nih.gov/10505625/)

[Kaplan DR, et al. The Trk signal transduction pathway. Seminars in Cancer Biology. 1997.](https://pubmed.ncbi.nlm.nih.gov/9441635/)

[Huang EJ, et al. Trk receptors: roles in neuronal development and function. Cell. 2001.](https://pubmed.ncbi.nlm.nih.gov/11414746/)

External Links

[NCBI Gene: NTRK1](https://www.ncbi.nlm.nih.gov/gene/4914)
[UniProt: P35579](https://www.uniprot.org/uniprot/P35579)
[OMIM: 191315](https://www.omim.org/entry/191315)
[HGNC: NTRK1](https://www.genenames.org/data/hgnc_data.php?appid=2&hgnc_id=11918)
[PharmGKB: NTRK1](https://www.pharmgkb.org/gene/PA162410000)

Pathway Diagram

The following diagram shows the key molecular relationships involving ntrk1 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

Pathway Diagram

The following diagram shows the key molecular relationships involving ntrk1 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

entities-ntrk1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	entities-ntrk1
kg_node_id	None
entity_type	general
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ffbaf0c3ee39
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-ntrk1'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

9

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ntrk1

NTRK1 Gene - Neurotrophic Receptor Tyrosine Kinase 1

Introduction

Gene Overview

NTRK1 Gene - Neurotrophic Receptor Tyrosine Kinase 1

Introduction

Gene Overview

Protein Structure and Function

Receptor Architecture

Signal Transduction Pathways

PI3K/Akt Pathway

MAPK/ERK Pathway

PLC-γ Pathway

Physiological Roles

Expression Pattern

Tissue Distribution

Brain Expression

Disease Associations

Congenital Insensitivity to Pain with Anhidrosis (CIPA)

Alzheimer's Disease

Cholinergic Neuron Survival

Neuroprotective Effects

Clinical Trials

Therapeutic Strategies

Parkinson's Disease

Neuroblastoma

Pathophysiology in Neurodegeneration

Mechanisms of Neuroprotection

1. Anti-apoptotic Signaling

2. Amyloid-beta Modulation

3. Tau Phosphorylation Regulation

4. Synaptic Function

Why Cholinergic Neurons Are Vulnerable

Therapeutic Implications

Current Approaches

Protein and Gene Therapy

Small Molecule Agonists

Advantages of TrkA Agonists

Clinical Development

Future Directions

Related Proteins and Pathways

See Also

References

External Links

Pathway Diagram

Pathway Diagram

💬 Discussion